iiinova — where your digital self keeps evolving

Reposted by Mariana Brandao

EACR - European Association for Cancer Research @helloeacr.bsky.social · 04/02/2025

Today on #WorldCancerDay we're proud to support our 13K members worldwide as they work on the fundamental research that leads to treatment breakthroughs. #UnitedbyUnique

0278

Mariana Brandao @marianabrandao0.bsky.social · 13/12/2024

What's the Land of Tomorrow of #IO in #NSCLC? At #ESMOImmune2024 I had the honor to discuss the data on 🔴 PDC*lung01 vaccine + Pembro in 1L PD-L1 high 🔴 Inupadenant +carbo/pem after IO failure 🔴 Effectiveness & immunophenotype in orphan genomic alterations @oncoalert.bsky.social #lcsm

052

Mariana Brandao @marianabrandao0.bsky.social · 13/12/2024

Exciting data at #ESMOImmumo2024 showed by George Coukos on adoptive immune cell therapies: 🔵 Nb of reactive antitumor TILs that are injected correlate with response 🔵 How to improve #TIL treatments in pts with #melanoma @oncoalert.bsky.social

051

Mariana Brandao @marianabrandao0.bsky.social · 13/12/2024

How to counteract the immunosuppressive action of #adenosine in #TNBC? @laubdh.bsky.social explains her journey from bench to bedside with the SYNERGY and NeoCheckRay trials & the intense ongoing TR to understand who're the pts who benefit from anti-CD73 🔬👏💪 @oncoalert.bsky.social #ESMOImmuno2024

081

Reposted by Mariana Brandao

Anouk Goudsmit @anoukgst.bsky.social · 12/12/2024

When @marianabrandao0.bsky.social makes us travel from Geneva #ESMOImmuno24 to Tomorrowland and the Smurf Village throught a brillant discussion of 3 mini orals about treatment strategies for NSCLC patients. Thank you!

052

Reposted by Mariana Brandao

Laurence Buisseret @laubdh.bsky.social · 12/12/2024

Excellent discussion by @marianabrandao0.bsky.social on treatment of patients with #NSCLC #ESMOImmuno24 Insightful perspectives on recent advances!

041

Reposted by Mariana Brandao

Jon Lim, FRCP PhD @drjonlim.bsky.social · 12/12/2024

🧑‍⚕️ Calling #YoungOncologists - Have an idea for a trial or study? The annual #MCCRWorkshop now open for applications! 🗓️ Deadline 31 Jan 2025 @mcrcnews.bsky.social 🔗 ow.ly/2KEB50UohRW

024

Reposted by Mariana Brandao

Philippe Aftimos, MD @aftimosp.bsky.social · 03/12/2024

Initiation visit this morning at Institut Jules Bordet of the EmpowHER 303 phase 3 study of anti-HER2 bispecific antibody zanidatamab in combination with chemo vs trastuzumab and chemo in HER2+ MBC. clinicaltrials.gov/study/NCT064... #bcsm

175

Mariana Brandao @marianabrandao0.bsky.social · 29/11/2024

Congratulations @mattiarediti.bsky.social & Christos Sotiriou for this extraordinary work on HER2+ breast cancer!! 💪👏👏

010

Reposted by Mariana Brandao

Jarushka Naidoo @drjnaidoo.bsky.social · 29/11/2024

Impact of cycle 1 irAEs on ICI outcomes: - 683pts from SWOG DART trial - g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001 - g3+ irAEs = ⬇️OS HR 1.41 p= .025 - g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002 Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social academic.oup.com/jnci/advance...

academic.oup.com

First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors

AbstractBackground. Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluate

02715

Mariana Brandao @marianabrandao0.bsky.social · 29/11/2024

Impressive talk by Barbara Pistilli on #ADCs at the 18th Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice by #BSMO & #JulesBordet 🚨 🔴How ADCs are made? 🔴What mechanisms of resistance? 🔴How to improve efficacy? @oncoalert.bsky.social

0123

Reposted by Mariana Brandao

Jon Lim, FRCP PhD @drjonlim.bsky.social · 25/11/2024

🧑‍🔬🏛️👩‍⚕️ Lots of our #CancerImmunology community now here 🦋, including @jimallisonphd.bsky.social 🏅! #AcademicSky #ImmunoSky #OncSky #StarterPack 1 is already full 🙌, so starting a another one. Let's continue growing! - Pack 1️⃣: go.bsky.app/PRdmHCP - Pack 2️⃣: go.bsky.app/93eqJbs

205017

Mariana Brandao @marianabrandao0.bsky.social · 25/11/2024

Don't miss the next #ESMO Virtual Journal Club on Wed 4/Dec🔎📃 we'll discuss: #LAURA trial: Osi after CRT in #NSCLC 🫁 #RUBY trial: dostarlimab +carbo/paclitaxel in #endometrialcancer 🚨Don't forget to register! 👇 @oncoalert.bsky.social

esmo.org

ESMO Virtual Journal Club: December 2024

This ESMO Webinar Series is available to all ESMO Members

052

Reposted by Mariana Brandao

Philippe Aftimos, MD @aftimosp.bsky.social · 13/11/2024

18th edition of the Belgian Symposium on the Integration of Molecular Biology - Friday 29/11 and Saturday 30/11/2024 Organized by the Institut Jules Bordet, Belgian Society of Medical Oncology (BSMO) and the Oncodistinct network www.bordet.be/fr/18th-edit...

022

Reposted by Mariana Brandao

Philippe Aftimos, MD @aftimosp.bsky.social · 23/11/2024

Institut Jules Bordet (part of the) medical oncology team dinner 🤗 @mignatiadis.bsky.social is already here 🦋 and we are lobbying for others to migrate!

042